PE20161236A1 - Compuesto de triazina y su uso para fines medicos - Google Patents
Compuesto de triazina y su uso para fines medicosInfo
- Publication number
- PE20161236A1 PE20161236A1 PE2016001506A PE2016001506A PE20161236A1 PE 20161236 A1 PE20161236 A1 PE 20161236A1 PE 2016001506 A PE2016001506 A PE 2016001506A PE 2016001506 A PE2016001506 A PE 2016001506A PE 20161236 A1 PE20161236 A1 PE 20161236A1
- Authority
- PE
- Peru
- Prior art keywords
- halogen
- hydroxy
- triazine compound
- medical purposes
- triazin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se refiere a un compuesto derivado de triazina de formula I o una de sus sales farmaceuticas, donde: X es CH o N; Cy es un anillo de formula (a) o (b) en donde R1 es halogeno, alquilo C1-C6, entre otros; R2 es halogeno, hidroxi, entre otros; R3 es halogeno, hidroxi, entre otros; R4 es hidrogeno, halogeno, entre otros; R5 es halogeno, hidroxi; entre otros; m1 es 0, 1, 2 o 3. Son compuestos preferidos: N-{4-cloro-3-[4-(4-ciclopropilmetoxifenil)-6-hidroxi-1,3,5-triazin-2-il]bencil}-3,3,3-trifluoro-2-metil-2-trifluorometilpropionamida; 4-[2-(6-metilpiridin-2-ilmetoxi)-6-trifluorometilfenil]-6-(4-feniletinilfenil)-1,3,5-triazin-2-ol; entre otros. Dichos compuestos son inhibidores de mPGES-1, utiles en el tratamiento del dolor, traumatismo, cancer, entre otros
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014031035 | 2014-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161236A1 true PE20161236A1 (es) | 2016-11-23 |
Family
ID=53878341
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000546A PE20211548A1 (es) | 2014-02-20 | 2015-02-19 | Compuesto de triazina y su uso para fines medicos |
| PE2016001506A PE20161236A1 (es) | 2014-02-20 | 2015-02-19 | Compuesto de triazina y su uso para fines medicos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000546A PE20211548A1 (es) | 2014-02-20 | 2015-02-19 | Compuesto de triazina y su uso para fines medicos |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20150266834A1 (es) |
| EP (2) | EP3109240B1 (es) |
| JP (4) | JP6461637B2 (es) |
| KR (1) | KR102360699B1 (es) |
| CN (1) | CN106232585B (es) |
| AR (1) | AR099498A1 (es) |
| AU (1) | AU2015219920B2 (es) |
| BR (1) | BR112016018341B1 (es) |
| CA (1) | CA2936408C (es) |
| CL (1) | CL2016002091A1 (es) |
| CY (1) | CY1121261T1 (es) |
| DK (1) | DK3109240T3 (es) |
| ES (1) | ES2704922T3 (es) |
| HR (1) | HRP20182134T1 (es) |
| IL (1) | IL247319B (es) |
| LT (1) | LT3109240T (es) |
| MX (1) | MX369217B (es) |
| MY (1) | MY183605A (es) |
| PE (2) | PE20211548A1 (es) |
| PH (1) | PH12016501651A1 (es) |
| PL (1) | PL3109240T3 (es) |
| PT (1) | PT3109240T (es) |
| RS (1) | RS58235B1 (es) |
| RU (1) | RU2692789C2 (es) |
| SA (1) | SA516371701B1 (es) |
| SG (1) | SG11201606902QA (es) |
| SI (1) | SI3109240T1 (es) |
| SM (1) | SMT201800684T1 (es) |
| TR (1) | TR201821158T4 (es) |
| TW (1) | TWI651310B (es) |
| WO (1) | WO2015125842A1 (es) |
| ZA (1) | ZA201606449B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| CA2972366C (en) * | 2014-12-24 | 2020-04-21 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
| US11078412B2 (en) * | 2015-03-04 | 2021-08-03 | Shimadzu Corporation | Polyamine and tyramine analysis method using pyrene containing fluorescence derivatization reagent and excimer fluorescence |
| MX375283B (es) * | 2015-08-17 | 2025-03-06 | Japan Tobacco Inc | Compuesto hidroxitriazina y su uso medico. |
| JP6817952B2 (ja) * | 2015-10-29 | 2021-01-20 | あすか製薬株式会社 | ピリミジン誘導体 |
| GB201603311D0 (en) * | 2016-02-25 | 2016-04-13 | Jakobsson Per Johan | New uses and methods |
| JP7036792B2 (ja) * | 2016-08-01 | 2022-03-15 | アプティニックス インコーポレイテッド | スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用 |
| JP2019527232A (ja) | 2016-08-01 | 2019-09-26 | アプティニックス インコーポレイテッド | スピロ−ラクタムｎｍｄａ修飾因子及びこれを用いた方法 |
| WO2019002183A1 (de) * | 2017-06-26 | 2019-01-03 | Merck Patent Gmbh | Verfahren zur herstellung substituierter stickstoffhaltiger heterocyclen |
| CN114502163A (zh) * | 2019-07-22 | 2022-05-13 | 安吉昂生物医药公司 | 作为rho相关卷曲螺旋激酶(rock)抑制剂的乙炔基杂环 |
| US11786538B2 (en) * | 2019-12-11 | 2023-10-17 | Somerset Therapeutics, Llc | Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties |
| KR102157466B1 (ko) * | 2020-05-19 | 2020-09-17 | 동아대학교 산학협력단 | 헥사하이드로트리아진 유도체를 포함하는 방광암의 예방, 개선 또는 치료용 조성물 |
| EP4289832A4 (en) | 2021-02-02 | 2024-12-04 | ASKA Pharmaceutical Co., Ltd. | Pyrimidine derivative |
| JPWO2024010015A1 (es) | 2022-07-06 | 2024-01-11 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH473818A (de) | 1964-03-18 | 1969-06-15 | Ciba Geigy | Verfahren zur Herstellung von neuen Hydroxyphenyl-1,3,5-triazinen und deren Verwendung |
| EP0051067A1 (en) * | 1980-04-22 | 1982-05-12 | Commonwealth Scientific And Industrial Research Organisation | Triazine synthesis |
| SU1313854A1 (ru) | 1985-04-17 | 1987-05-30 | Институт Органической Химии Ан Армсср | Способ получени смеси 2-оксо-2,3-дигидро-4,6,-бис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина и 2,4,6-трис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина |
| DE19543730A1 (de) * | 1995-11-23 | 1997-05-28 | Ciba Geigy Ag | Bis-Resorcinyl-Triazine |
| TW520362B (en) * | 1996-12-05 | 2003-02-11 | Amgen Inc | Substituted pyrimidine compounds and pharmaceutical composition comprising same |
| US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| AR048564A1 (es) * | 1996-12-05 | 2006-05-10 | Amgen Inc | Compuestos de pirimidina sustituidos,composicion farmaceutica y usos para la fabricacion de medicamentos particularmente para el tratamiento de enfermedades mediadas por tnf-alfa, il-1 beta, il-6 y/o il-8 |
| ZA9710727B (en) | 1996-12-05 | 1998-06-12 | Amgen Inc | Substituted pyrimidine compounds and methods of use. |
| GB9726987D0 (en) | 1997-12-22 | 1998-02-18 | Glaxo Group Ltd | Compounds |
| NZ514144A (en) | 1999-04-01 | 2001-09-28 | Pfizer Prod Inc | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
| US20040082627A1 (en) * | 2002-06-21 | 2004-04-29 | Darrow James W. | Certain aromatic monocycles as kinase modulators |
| MX2009010558A (es) | 2007-04-03 | 2009-10-22 | Du Pont | Fungicidas de benceno sustituido. |
| BRPI0913343B1 (pt) | 2008-06-04 | 2018-01-23 | Adeka Corporation | Método para produção do composto 2,4,6-tri (hidroxifenil)-1,3,5-triazina |
| JP5388270B2 (ja) | 2008-06-04 | 2014-01-15 | 株式会社Ａｄｅｋａ | ２，４，６−トリス（ヒドロキシフェニル）−１，３，５−トリアジン化合物の製造方法 |
| EP2138488A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
| CN101747282A (zh) * | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| CA2811154C (en) | 2009-09-23 | 2019-01-08 | Albert Einstein College Of Medicine Of Yeshiva University | Prostaglandin transporter inhibitors and uses thereof |
| WO2011048004A1 (en) | 2009-10-23 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin e2 synthase-1 |
| US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| AR086254A1 (es) * | 2011-05-26 | 2013-11-27 | Lilly Co Eli | Derivados de imidazol utiles para el tratamiento de artritis |
| FR2983859B1 (fr) | 2011-12-12 | 2014-01-17 | Sanofi Sa | Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique |
| AU2013207289B2 (en) * | 2012-01-06 | 2017-09-21 | Les Laboratoires Servier | Therapeutically active compounds and their methods of use |
| WO2013174947A1 (en) | 2012-05-23 | 2013-11-28 | Stemergie Biotechnology Sa | Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| JP2014031035A (ja) | 2012-08-01 | 2014-02-20 | Yamaha Motor Co Ltd | 原動機付き鞍乗型車両 |
| WO2015059618A1 (en) * | 2013-10-22 | 2015-04-30 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS |
| TWI651310B (zh) | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| CN105586773A (zh) * | 2014-11-13 | 2016-05-18 | 东丽纤维研究所（中国）有限公司 | 一种拒水抗紫外纺织品及其生产方法和用途 |
| MX375283B (es) | 2015-08-17 | 2025-03-06 | Japan Tobacco Inc | Compuesto hidroxitriazina y su uso medico. |
| JP6817952B2 (ja) * | 2015-10-29 | 2021-01-20 | あすか製薬株式会社 | ピリミジン誘導体 |
-
2015
- 2015-02-17 TW TW104105551A patent/TWI651310B/zh not_active IP Right Cessation
- 2015-02-19 EP EP15751885.3A patent/EP3109240B1/en active Active
- 2015-02-19 CN CN201580020793.6A patent/CN106232585B/zh active Active
- 2015-02-19 TR TR2018/21158T patent/TR201821158T4/tr unknown
- 2015-02-19 PE PE2021000546A patent/PE20211548A1/es unknown
- 2015-02-19 KR KR1020167025241A patent/KR102360699B1/ko not_active Expired - Fee Related
- 2015-02-19 PE PE2016001506A patent/PE20161236A1/es unknown
- 2015-02-19 BR BR112016018341-0A patent/BR112016018341B1/pt not_active IP Right Cessation
- 2015-02-19 US US14/626,243 patent/US20150266834A1/en not_active Abandoned
- 2015-02-19 EP EP18201469.6A patent/EP3456713A1/en not_active Withdrawn
- 2015-02-19 ES ES15751885T patent/ES2704922T3/es active Active
- 2015-02-19 JP JP2015030157A patent/JP6461637B2/ja active Active
- 2015-02-19 DK DK15751885.3T patent/DK3109240T3/en active
- 2015-02-19 HR HRP20182134TT patent/HRP20182134T1/hr unknown
- 2015-02-19 PT PT15751885T patent/PT3109240T/pt unknown
- 2015-02-19 LT LTEP15751885.3T patent/LT3109240T/lt unknown
- 2015-02-19 AR ARP150100484A patent/AR099498A1/es active IP Right Grant
- 2015-02-19 SI SI201530563T patent/SI3109240T1/sl unknown
- 2015-02-19 MX MX2016010875A patent/MX369217B/es active IP Right Grant
- 2015-02-19 AU AU2015219920A patent/AU2015219920B2/en not_active Ceased
- 2015-02-19 RS RS20181563A patent/RS58235B1/sr unknown
- 2015-02-19 PL PL15751885T patent/PL3109240T3/pl unknown
- 2015-02-19 RU RU2016137263A patent/RU2692789C2/ru active
- 2015-02-19 WO PCT/JP2015/054519 patent/WO2015125842A1/ja not_active Ceased
- 2015-02-19 CA CA2936408A patent/CA2936408C/en active Active
- 2015-02-19 MY MYPI2016703028A patent/MY183605A/en unknown
- 2015-02-19 SG SG11201606902QA patent/SG11201606902QA/en unknown
- 2015-02-19 SM SM20180684T patent/SMT201800684T1/it unknown
-
2016
- 2016-08-17 IL IL24731916A patent/IL247319B/en active IP Right Grant
- 2016-08-18 PH PH12016501651A patent/PH12016501651A1/en unknown
- 2016-08-18 SA SA516371701A patent/SA516371701B1/ar unknown
- 2016-08-18 CL CL2016002091A patent/CL2016002091A1/es unknown
- 2016-09-19 ZA ZA2016/06449A patent/ZA201606449B/en unknown
-
2018
- 2018-12-19 CY CY20181101359T patent/CY1121261T1/el unknown
- 2018-12-26 JP JP2018241974A patent/JP2019065036A/ja active Pending
-
2019
- 2019-04-26 US US16/396,503 patent/US20200087266A1/en not_active Abandoned
-
2021
- 2021-01-05 JP JP2021000347A patent/JP2021054856A/ja not_active Ceased
-
2022
- 2022-01-14 US US17/575,931 patent/US12398111B2/en active Active
- 2022-06-17 JP JP2022097960A patent/JP2022120173A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| CY1123994T1 (el) | Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4 | |
| CY1121694T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| EA202091115A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| PE20161438A1 (es) | Inhibidores de desmetilasa 1 especifica a lisina | |
| PE20170695A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| PE20170268A1 (es) | Compuestos de heteroarilo para la inhibicion de cinasa | |
| PE20191541A1 (es) | Composiciones y metodos para inhibir la accion de la arginasa | |
| PE20161384A1 (es) | Ciclopropilaminas como inhibidores de lsd 1 | |
| EA201791305A1 (ru) | Конденсированные пиримидины для лечения вич | |
| PH12016501440A1 (en) | Novel heterocyclic compounds | |
| EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| CY1123494T1 (el) | Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2 | |
| PE20171329A1 (es) | Agentes inmunorreguladores | |
| PE20170662A1 (es) | Compuestos de aminopiridiloxipirazol | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| MX388321B (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
| TN2017000158A1 (en) | Carbazole derivatives | |
| PE20191142A1 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| MX390051B (es) | Antagonistas de ep4. |